Andrea Apolo

American oncologist

Andrea B. Apolo is an American oncologist known for her work in the field of genitourinary oncology. She is a senior investigator and head of the Bladder Cancer Section at the National Cancer Institute (NCI), where she conducts research on novel therapies for urothelial carcinoma and other genitourinary malignancies.

Early life and education

Andrea Apolo was born and raised in the United States. She developed an early interest in medicine and pursued her undergraduate studies at Columbia University, where she earned a Bachelor of Arts degree in biochemistry. Following her undergraduate education, she attended the Albert Einstein College of Medicine, obtaining her MD degree.

Career

After completing her medical degree, Dr. Apolo pursued a residency in internal medicine at NewYork-Presbyterian Hospital, affiliated with Weill Cornell Medical College. She then completed a fellowship in medical oncology at the National Cancer Institute, where she focused on genitourinary cancers.

Andrea Apolo

Dr. Apolo joined the NCI as a staff clinician and quickly rose through the ranks due to her dedication and contributions to the field. She is currently a senior investigator and head of the Bladder Cancer Section in the Genitourinary Malignancies Branch. Her research primarily focuses on developing and testing new therapeutic strategies for bladder cancer, including immunotherapy and targeted therapy.

Research and contributions

Dr. Apolo's research has significantly advanced the understanding and treatment of bladder cancer. She has been involved in numerous clinical trials investigating the efficacy of novel agents in treating advanced urothelial carcinoma. Her work has contributed to the development of new treatment protocols that have improved patient outcomes.

In addition to her clinical research, Dr. Apolo is actively involved in translational research, aiming to bridge the gap between laboratory findings and clinical applications. Her efforts have led to the identification of potential biomarkers for bladder cancer, which could aid in early detection and personalized treatment approaches.

Professional affiliations and awards

Dr. Apolo is a member of several professional organizations, including the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). She has received numerous awards for her contributions to oncology, including recognition from the NCI for her outstanding research and leadership in the field.

Related pages

• Bladder cancer
• Urothelial carcinoma
• National Cancer Institute
• Immunotherapy